Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Up to this day, little is known whether the extent of brain damage in patients with SAH correlates with the degree neurogenic myocardial injury and neurogenic lung injury.
This is a prospective observational study designed to asses relationship between catecholamine surge and development of myocardial and lung injury in subarachnoid haemorrhage patients.
Multiple forms of brain damage, primarily, subarachnoid haemorrhage (SAH) are frequently accompanied by neurogenic myocardial injury with changes in the electrocardiogram, accompanied by the release of markers of myocardial injury. This form of cardiac dysfunction is thought to be mediated by cellular toxicity associated with catecholamine release. Central nervous system damage in the course of intracranial haemorrhage may, in a similar pathogenic pathway, lead to neurogenic lung injury. Up to this day, little is known whether the extent of brain damage in patients with SAH correlates with the degree of neurogenic myocardial injury. Moreover, it remains unknown what is the full clinical picture and duration of this type of myocardial injury and how often it co-occurs with neurogenic lung injury. Such analysis is a fundamental and most important step in optimising the treatment of these patients.
Methods: In this prospective observational study the authors aim to recruit 30 patients with subarachnoid haemorrhage, requiring hospitalization in the Intensive Care Unit. The patients will be monitored for elevation in cardiac damage markers (hs-TnT, CPK, CK-MB, NT-proBNP) and worsening of respiratory conditions, defined by need for more invasive ventilation parameters, and subsequent changes in arterial blood gas. The above mentioned parameters will be assessed every 12 hours. Additionally, the patients will be screened for an elevation in catecholamine metabolite (metanephrine) concentration in 12-hour urine collection.
Hypothesis to be tested: Myocardial and lung injury in SAH patients is timely-associated with an increase in metanephrine concentration in urine.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with subarachnoid haemorrhage | Patients aged 18 or older hospitalized in the Intensive Care Unit with Subarachnoid Haemorrhage. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| hs-TnT (high-sensitive cardiac troponin T) plasma concentration | Diagnostic Test | hs-TnT plasma concentration measured once every 12 hours |
|
| Measure | Description | Time Frame |
|---|---|---|
| In-hospital death (number of patients) | Death of the patient during the first 7 days of hospitalization. | 7 days |
| Number of Patients with elevation in hs-TnT levels | hs-TnT treated as myocardial injury biomarker | 7 days |
| Number of Patients with elevation in NT-proBNP levels | NT-proBNP treated as myocardial injury biomarker | 7 days |
| Number of Patients with elevation in creatine kinase levels | Creatine kinase treated as myocardial injury biomarker | 7 days |
| Number of Patients with elevation in creatine kinase MB levels | Creatine kinase MB treated as myocardial injury biomarker | 7 days |
| Number of Patients with a decrease in Horowitz index | The decrease in Horowitz index treated as a sign of need for more invasive ventilation parameters with subsequent blood gas changes | 7 days |
| Number of Patients with need of increased FiO2 | Need of increased FiO2 treated as a sign of need for more invasive ventilation parameters with subsequent blood gas changes | 7 days |
| Number of Patients with need of increased PEEP values |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with subarachnoid haemorrhage admitted to the Intensive Care Unit.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Natalia Rachfalska | Contact | +48 32 789 42 01 | n.rachfalska@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Ćukasz Krzych, PhD | University Clinical Center prof. K. GibiĆski of the Medical University of Silesia in Katowice | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Clinical Center prof. K. GibiĆski of the Medical University of Silesia in Katowice | Recruiting | Katowice | Silesian Voivodeship | 40-752 | Poland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34308493 | Background | Osgood ML. Aneurysmal Subarachnoid Hemorrhage: Review of the Pathophysiology and Management Strategies. Curr Neurol Neurosci Rep. 2021 Jul 26;21(9):50. doi: 10.1007/s11910-021-01136-9. | |
| 32545225 | Background | Hofman M, Hajder N, Duda I, Krzych LJ. A Questionnaire Survey of Management of Patients with Aneurysmal Subarachnoid Haemorrhage in Poland. Int J Environ Res Public Health. 2020 Jun 11;17(11):4161. doi: 10.3390/ijerph17114161. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Urine
| CK-MB (creatine kinase myocardial band) plasma concentration | Diagnostic Test | CK-MB plasma concentration measured every 12 hours |
|
| CPK (creatine phosphokinase) plasma concentration | Diagnostic Test | CPK plasma concentration measured every 12 hours |
|
| NT-proBNP (N-terminal prohormone of brain natriuretic peptide) plasma concentration | Diagnostic Test | NT-proBNP plasma concentration measured every 12 hours |
|
| Metanephrine concentration in urine | Diagnostic Test | Metanephrine concentration measured in 12-hour urine collection using spectrophotometry. |
|
Need of increased PEEP values treated as a sign of need for more invasive ventilation parameters with subsequent blood gas changes |
| 7 days |
| Number of Patients with need for the use of neuro-muscular blocking agents | Need for the use of neuro-muscular blocking agents treated as a sign of need for more invasive ventilation parameters with subsequent blood gas changes | 7 days |
| 24526502 | Background | Wybraniec MT, Mizia-Stec K, Krzych L. Neurocardiogenic injury in subarachnoid hemorrhage: A wide spectrum of catecholamin-mediated brain-heart interactions. Cardiol J. 2014;21(3):220-8. doi: 10.5603/CJ.a2014.0019. Epub 2014 Feb 14. |
| 24462197 | Background | Wybraniec M, Mizia-Stec K, Krzych L. Stress cardiomyopathy: yet another type of neurocardiogenic injury: 'stress cardiomyopathy'. Cardiovasc Pathol. 2014 May-Jun;23(3):113-20. doi: 10.1016/j.carpath.2013.12.003. Epub 2013 Dec 27. |
| 24560705 | Background | Veeravagu A, Chen YR, Ludwig C, Rincon F, Maltenfort M, Jallo J, Choudhri O, Steinberg GK, Ratliff JK. Acute lung injury in patients with subarachnoid hemorrhage: a nationwide inpatient sample study. World Neurosurg. 2014 Jul-Aug;82(1-2):e235-41. doi: 10.1016/j.wneu.2014.02.030. Epub 2014 Feb 20. |
| 33083966 | Background | Mazeraud A, Robba C, Rebora P, Iaquaniello C, Vargiolu A, Rass V, Bogossian EG, Helbok R, Taccone FS, Citerio G. Acute Distress Respiratory Syndrome After Subarachnoid Hemorrhage: Incidence and Impact on the Outcome in a Large Multicenter, Retrospective Cohort. Neurocrit Care. 2021 Jun;34(3):1000-1008. doi: 10.1007/s12028-020-01115-x. Epub 2020 Oct 20. |
| 34373566 | Background | Anetsberger A, Jungwirth B, Blobner M, Ringel F, Bernlochner I, Heim M, Bogdanski R, Wostrack M, Schneider G, Meyer B, Graessner M, Baumgart L, Gempt J. Association of Troponin T levels and functional outcome 3 months after subarachnoid hemorrhage. Sci Rep. 2021 Aug 9;11(1):16154. doi: 10.1038/s41598-021-95717-w. |
| ID | Term |
|---|---|
| D055370 | Lung Injury |
| D013345 | Subarachnoid Hemorrhage |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D013898 | Thoracic Injuries |
| D014947 | Wounds and Injuries |
| D020300 | Intracranial Hemorrhages |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D014554 | Urination |
| ID | Term |
|---|---|
| D014553 | Urinary Tract Physiological Phenomena |
| D012101 | Reproductive and Urinary Physiological Phenomena |
Not provided
Not provided